Sees net sales of $1.05 billion to $1.10 billion, 6% growth, consensus $1.21B; Net income of $36 million to $42 million; Diluted EPS of $0.89 to $1.04; Adjusted EBITDA of $124 million to $132 million, 15% growth; Adjusted net income of $55 million to $60 million, 18% growth; Adjusted diluted EPS of $1.34 to $1.48, 18% growth; Adjusted effective tax rate of 24% to 26%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PAHC:
- Phibro Animal Health reports Q1 adjusted EPS 35c, consensus 25c
- Is PAHC a Buy, Before Earnings?
- Phibro Animal Health Expands Portfolio with Zoetis Acquisition
- Phibro Animal Health initiated with a Neutral at JPMorgan
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
